The Wall Street Journal has released an article about a new scientific study questionning the value of Costly Cancer-drug combinations.

A new study is stirring debate about whether the benefits of cancer drugs are worth their cost“ A new study is stirring debate about whether the benefits of cancer drugs are worth their cost, particularly as drugmakers develop treatments that combine multiple pricey drugs. The study of about 4,800 women with an aggressive type of breast cancer found that adding Roche Holding AG’s RHHBY +0.28% drug Perjeta to the company’s older treatment Herceptin conferred a slight benefit versus Herceptin alone, after the women had undergone surgery to remove tumors. Some 94.1% of women receiving the combination in the study stayed free of invasive breast cancer three years after the start of treatment, versus 93.2% of those who received Herceptin alone—a difference of less than a percentage point. That modest benefit comes at a high price: more than doubling the one-year treatment cost to $158,000 a patient from $74,500. The combination also had higher rates of certain side effects than Herceptin alone, including severe diarrhea. […]”(1)

I find interesting that doctors complain that little tests are being done to verify which patients are to benefit from the Perjeta-Herceptin combinations, especially considering that a test developed by the Research Genetic Cancer Center (R.G.C.C.), a genetic research laboratory whose headquarters are located in Greece, is not an expensive test.2 R.G.C.C. has developed a patented membrane that is able to capture malignant cells from a simple blood sample. Then they match those malignant cells recovered from the blood sample with a panel of known anti-cancer agents and see what will indeed work. No more guessing, no more false hope. Originally created to allow oncologists to select the chemotherapy treatment that will be the most effective against each specific cancer, it also allows other practitioners to know what may be the best natural approach to cancer therapy as well. In Japan, where the test is routinely prescribed, a specific mix of Pao pereira, Rauwolfia vomitoria and golden Ginkgo biloba extracts has been confirmed to be able to induce apoptosis (death) of the cancer cells for many patients suffering from various kind of cancer. A Japanese doctor has been kind enough to share his data with The Beljanski Foundation.